Log in or Sign up for Free to view tailored content for your specialty!
Cell Therapy News
Exploring alternatives to CAR T-cell therapy
In this installment of In Practice, Ryan D. Cassaday, MD, explains how to negotiate the delicate balancing act required when discussing alternatives to chimeric antigen receptor T-cell therapy with patients and referring colleagues.
Discovery of cell surface protein may lead to CAR-T for inflammatory diseases
Cellular senescence has both positive and negative effects in the body.
Log in or Sign up for Free to view tailored content for your specialty!
FDA clears IND application for off-the-shelf, BCMA-directed CAR-T for advanced myeloma
The FDA cleared an investigational new drug application for CYAD-211, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.
Real-world CAR T-cell therapy as safe, effective as in clinical trial setting
Axicabtagene ciloleucel administered as standard of care appeared as safe and effective as when given during the agent’s pivotal clinical trial, according to study results published in Journal of Clinical Oncology.
Nine investigators to share $6.75 million for blood cancer research
Three organizations awarded grants totaling $6.75 million to fund research into blood cancers.
FDA clears IND application for stem cell-derived CAR-T targeting CD19-positive tumors
The FDA cleared an investigational new drug application for FT819, a chimeric antigen receptor T-cell therapy for the treatment of CD19-positive tumors, according to a press release from the agent’s manufacturer.
Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.
Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.
FDA places clinical hold on trial for off-the-shelf CAR-T for advanced myeloma
The FDA placed a clinical hold on a phase 1 study designed to evaluate UCARTCS1A for the treatment of patients with relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.
Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.